Le Lézard
Classified in: Health
Subject: FDA

RedDress Receives FDA 510(k) Clearance for RD1 System


Innovative Device for Wound Management

PARDES-HANNA, Israel, July 10, 2018 /PRNewswire/ -- RedDress Ltd announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its RD1 system.

RedDress Ltd.

RD1 is an innovative wound care product which enables health care providers to produce in real time, in vitro whole blood clots, for use as a chronic wound care product. It has been developed to address the need for cost effectiveness and clinical effectiveness of wound care.

The RD1 System is intended to be used at point-of-care for the safe and rapid preparation of whole blood clot from a small sample of a patient's own peripheral blood. Under the supervision of a healthcare professional, the whole blood clot produced by the RD1 System is topically applied for the management of exuding cutaneous wounds, such as leg ulcers, pressure ulcers, diabetic ulcers, and mechanically or surgically-debrided wounds.

The 510(k) clearance allows RedDress to introduce its innovative device technology to the U.S. market, where it will be marketed as the RD1 System for the indications for use cited above.

"The recent FDA clearance is a significant milestone for RedDress," said Alon Kushnir, Founder and CEO. "RedDress is pioneering a new technology for wound care management. RD1 is the first product utilizing our proprietary patented technology.  Our mission is to provide wound care technology that is engineered to improve patient outcomes."

About RedDress

RedDress, a private medical device company, developed a ground breaking, advanced wound care product, based on a patented technology to reproduce the natural process of the body to heal wounds. The company based in Israel, was founded in 2009 by Dr. Igal Kushnir, MD and Alon Kushnir and is focused on developing effective solutions that improve outcomes for patients. RedDress management has vast experience in bringing breakthrough medical ideas to successful commercialization. For more information, please visit www.reddress.co.il.

For More Information, Contact:

Email: [email protected]
Website: http://www.reddress.co.il/

Logo - https://mma.prnewswire.com/media/715699/RedDress_Ltd_Logo.jpg

 


These press releases may also interest you

at 22:03
The report titled "Contract Research Organization Services Market by Type (Clinical Research Services, Consulting Services, Data Management Services), Trial Phase (Phase I, Phase II, Phase III), Therapeutic Area, Molecule Type, End-User - Global...

at 21:30
Greenbrook TMS Inc. ("Greenbrook" or the "Company") today announced its fiscal year ended December 31, 2023 ("Fiscal 2023") operational and financial results. All values in this news release are in United States dollars, unless otherwise stated....

at 20:25
AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an alternative to the costly branded...

at 20:12
BCACC is pleased to announce that its Deputy Registrar, Kathy Lauriente, has been honoured with the Distinguished Service Award from Thompson Rivers University. The award recognizes stellar contributions to the University, community, and the public...

at 19:29
Suffolk DBT is proud to announce the completion of their initial expansion to accommodate the growing need for DBT therapy...

at 18:24
The scheduled merits hearing dates, April 26 and 29, 2024, in the above-named matter will proceed by videoconference. On April 26, 2024, the hearing will commence 11:15 a.m. Members of the public may observe the hearing by videoconference, by...



News published on and distributed by: